Track market-moving stories before they get noisy

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first quarter ended March 31, 2026.

(All results compared to prior-year comparative period, unless otherwise noted)

2026 Highlights and FY 2026 Outlook

Revenue of $403.5 million increased 21% compared to revenue of $333.0 millionClinician base increased 11% to 8,349 clinicians, a sequential net increase of 309 in the first quarterFirst quarter visit volumes increased 18% to 2.5 millionNet income of $14.2 million compared to net income of $0.7 millionAdjusted EBITDA of $51.1 million compared to Adjusted EBITDA of $34.6 millionNet cash provided by operations of $33.1 million in the first quarterFree Cash Flow generation of $22.3 million in the first quarterFor full year 2026, raising revenue expectations to $1.640 billion to $1.680 billion, Center Margin expectations to $547 million to $571 million, and Adjusted EBITDA of $200 million to $220 million “We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%,” said Dave Bourdon, CEO of LifeStance. “Our performance demonstrates that our differentiated model is meeting the societal trend of growing demand for mental healthcare. We also took an important step forward in our commitment to clinical excellence by announcing an outcomes study on approximately 180,000 LifeStance patients that showed roughly three quarters reported clinically significant improvement in anxiety and depression.”

          Financial Highlights           Q1 2026  Q1 2025  Y/Y (in millions)         Total revenue $403.5  $333.0   21%Income from operations  22.3   1.6  NM Center Margin  135.9   109.8   24%Net income  14.2   0.7  NM Adjusted EBITDA  51.1   34.6   48%As % of Total revenue:         Income from operations  5.5%  0.5%   Center Margin  33.7%  33.0%   Net income  3.5%  0.2%   Adjusted EBITDA  12.7%  10.4%               NM - not meaningful                        (All results compared to prior-year period, unless otherwise noted)

Revenue grew 21% to $403.5 million. Revenue growth in the first quarter was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.Income from operations was $22.3 million and net income was $14.2 million.Center Margin grew 24% to $135.9 million, or 33.7% of total revenue.Adjusted EBITDA increased 48% to $51.1 million, or 12.7% of total revenue. Adjusted EBITDA as a percentage of revenue increased in the first quarter as a result of higher total revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses. Balance Sheet, Cash Flow, and Capital Allocation

For the three months ended March 31, 2026, LifeStance generated $33.1 million cash flow from operations. The Company ended the first quarter with cash of $194.8 million and net long-term debt of $262.5 million.

2026 Guidance

LifeStance is providing the following outlook for 2026:

The Company is raising full year revenue to $1.640 billion to $1.680 billion, Center Margin to $547 million to $571 million, and Adjusted EBITDA to $200 million to $220 million.For the second quarter of 2026, the Company expects total revenue of $405 million to $425 million, Center Margin of $135 million to $147 million, and Adjusted EBITDA of $50 million to $60 million. Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, May 7, 2026 at 8:30 a.m. Eastern Time to discuss the first quarter 2026 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 8795477 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements

Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. These statements include, but are not limited to, statements with respect to: full year and second quarter guidance and management's related assumptions; business plans and objectives; our share repurchase authorization and repurchases thereunder; and other statements contained in this press release that are not historical facts. When used in this press release and on the related teleconference, words such as “may,” “will,” “should,” “could,” “intend,” “potential,” “continue,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “seek” and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be materially harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide healthcare services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial performance would be harmed; the impact on us of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company’s operating performance and prospects. This press release also refers to Free Cash Flow, which is calculated as net cash provided by (used in) operating activities less purchases of property and equipment. Management believes Free Cash Flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net income or income from operations.

Center Margin and Adjusted EBITDA anticipated for the second quarter of 2026 and full year 2026 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking second quarter of 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.

Consolidated Financial Information and Reconciliations

 CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except for par value)
   March 31, 2026  December 31, 2025 CURRENT ASSETS      Cash and cash equivalents $194,797  $248,642 Patient accounts receivable, net  122,916   95,710 Prepaid expenses and other current assets  38,198   71,848 Total current assets  355,911   416,200 NONCURRENT ASSETS      Property and equipment, net  161,468   161,583 Right-of-use assets  151,526   149,720 Intangible assets, net  175,141   177,665 Goodwill  1,296,999   1,293,346 Other noncurrent assets  4,837   5,419 Total noncurrent assets  1,789,971   1,787,733 Total assets $2,145,882  $2,203,933 LIABILITIES AND STOCKHOLDERS' EQUITY      CURRENT LIABILITIES      Accounts payable $4,292  $6,122 Accrued payroll expenses  117,306   143,327 Other accrued expenses  52,408   42,187 Operating lease liabilities, current  47,369   45,544 Other current liabilities  18,357   14,782 Total current liabilities  239,732   251,962 NONCURRENT LIABILITIES      Long-term debt, net  262,459   265,927 Operating lease liabilities, noncurrent  148,821   148,553 Deferred tax liability, net  16,408   16,408 Other noncurrent liabilities  1,046   68 Total noncurrent liabilities  428,734   430,956 Total liabilities $668,466  $682,918 COMMITMENTS AND CONTINGENCIES      STOCKHOLDERS’ EQUITY      Preferred stock – par value $0.01 per share; 25,000 shares authorized as of
March 31, 2026 and December 31, 2025; 0 shares issued and outstanding as
of March 31, 2026 and December 31, 2025  —   — Common stock – par value $0.01 per share; 800,000 shares authorized as of
March 31, 2026 and December 31, 2025; 387,813 and 388,318 shares
issued and outstanding as of March 31, 2026 and December 31, 2025,
respectively  3,878   3,883 Additional paid-in capital  2,267,921   2,325,758 Accumulated deficit  (794,383)  (808,626)Total stockholders' equity  1,477,416   1,521,015 Total liabilities and stockholders’ equity $2,145,882  $2,203,933            CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(unaudited)
(In thousands, except per share amounts)
   Three Months Ended March 31,   2026  2025 TOTAL REVENUE $403,476  $332,970 OPERATING EXPENSES      Center costs, excluding depreciation and
amortization shown separately below  267,544   223,179 General and administrative expenses  100,330   94,431 Depreciation and amortization  13,318   13,756 Total operating expenses $381,192  $331,366 INCOME FROM OPERATIONS $22,284  $1,604 OTHER EXPENSE      Loss on remeasurement of contingent consideration  (5)  — Transaction costs  (544)  — Interest expense, net  (1,793)  (3,073)Other expense  (182)  (1)Total other expense $(2,524) $(3,074)INCOME (LOSS) BEFORE INCOME TAXES  19,760   (1,470)INCOME TAX (PROVISION) BENEFIT  (5,517)  2,179 NET INCOME $14,243  $709 EARNINGS PER SHARE      Basic  0.04   0.00 Diluted  0.04   0.00 Weighted-average shares outstanding      Basic  387,264   383,272 Diluted  395,084   390,666        NET INCOME $14,243  $709 OTHER COMPREHENSIVE LOSS      Unrealized losses on cash flow hedge, net of tax  —   (317)COMPREHENSIVE INCOME $14,243  $392            CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
   Three Months Ended March 31,   2026  2025 CASH FLOWS FROM OPERATING ACTIVITIES      Net income $14,243  $709 Adjustments to reconcile net income to net cash provided by
(used in) operating activities:      Depreciation and amortization  13,318   13,756 Non-cash operating lease costs  10,717   10,231 Stock-based compensation  15,201   18,584 Amortization of discount and debt issue costs  251   251 Other, net  129   357 Change in operating assets and liabilities, net of businesses acquired:      Patient accounts receivable, net  (26,953)  (8,568)Prepaid expenses and other current assets  33,779   (4,515)Accounts payable  (1,017)  (77)Accrued payroll expenses  (26,362)  (17,540)Operating lease liabilities  (9,955)  (11,894)Other accrued expenses  9,758   (4,386)Net cash provided by (used in) operating activities $33,109  $(3,092)CASH FLOWS FROM INVESTING ACTIVITIES      Purchases of property and equipment  (10,767)  (7,168)Acquisitions of businesses, net of cash acquired  (3,144)  — Net cash used in investing activities $(13,911) $(7,168)CASH FLOWS FROM FINANCING ACTIVITIES      Payments of long-term debt  —   (1,813)Taxes related to net share settlement of equity awards  (23,936)  (8,162)Repurchases of common stock  (49,107)  — Net cash used in financing activities $(73,043) $(9,975)NET DECREASE IN CASH AND CASH EQUIVALENTS  (53,845)  (20,235)Cash and cash equivalents - beginning of period  248,642   154,571 CASH AND CASH EQUIVALENTS – END OF PERIOD $194,797  $134,336 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION      Cash paid for interest, net $77  $4,382 Cash paid for taxes, net of refunds $349  $609 SUPPLEMENTAL DISCLOSURES OF NON CASH INVESTING AND
FINANCING ACTIVITIES      Contingent consideration incurred in acquisitions of businesses $1,008  $— Acquisition of property and equipment included in liabilities $2,489  $2,348            RECONCILIATION OF INCOME FROM OPERATIONS TO CENTER MARGIN
   Three Months Ended March 31,   2026  2025 (in thousands)      Income from operations $22,284  $1,604 Adjusted for:      Depreciation and amortization  13,318   13,756 General and administrative expenses(1)  100,330   94,431 Center Margin $135,932  $109,791            (1) Represents salaries, wages and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock-based compensation for all employees.      RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
   Three Months Ended March 31,   2026  2025 (in thousands)      Net income $14,243  $709 Adjusted for:      Interest expense, net  1,793   3,073 Depreciation and amortization  13,318   13,756 Income tax provision (benefit)  5,517   (2,179)Loss on remeasurement of contingent consideration  5   — Stock-based compensation expense  15,201   18,584 Loss on disposal of assets  182   1 Transaction costs(1)  544   — Executive transition costs  —   185 Litigation costs(2)  (197)  205 Strategic initiatives(3)  86   — Real estate optimization and restructuring charges(4)  —   (45)Amortization of cloud-based software implementation costs(5)  418   357 Adjusted EBITDA $51,110  $34,646            (1) Primarily includes capital markets advisory, consulting, accounting and legal expenses related to the underwritten public offering of shares of our common stock by certain selling stockholders completed in the first quarter of 2026. (2) Litigation costs, net of insurance recoveries, include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case (e.g., complex class action litigation), (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy. During each of the three months ended March 31, 2026 and 2025, litigation costs included cash expenses related to certain litigation matters, including a privacy class action litigation, and for the three months ended March 31, 2025, a compensation model class action litigation. (3) Strategic initiatives consist of expenses directly related to evaluating and implementing a critical enterprise-wide scalable electronic health resources system in connection with our significant expansion. Strategic initiatives represents costs, such as third-party consulting costs and one-time costs, that are not part of our ongoing operations related to this enterprise-wide system. We considered the frequency and scale of this enterprise upgrade when determining that the expenses were not normal, recurring operating expenses. (4) Real estate optimization and restructuring charges consist of cash expenses and non-cash charges related to our real estate optimization initiative, which included certain asset impairment and disposal costs, certain gains and losses related to early lease terminations, and exit and disposal costs related to our real estate optimization initiative to consolidate our physical footprint during 2023. As the decision to close these centers was part of a significant strategic project driven by a historic shift in behavior, the magnitude of center closures was greater than what would be expected as part of ordinary business operations and did not constitute normal recurring operating activities. During the three months ended March 31, 2025, real estate optimization and restructuring charges consisted of certain gains and losses related to early lease terminations of previously abandoned real estate leases in 2023. (5) Represents amortization of capitalized implementation costs related to cloud-based software arrangements that are included within general and administrative expenses included in our unaudited consolidated statements of operations and comprehensive income.

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced that pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”), certain stockholders of the Company (the “Selling Stockholders”) intend to offer 35,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.

In addition, the Company has authorized the concurrent purchase from the underwriter of 6,000,000 shares of Common Stock (the “Repurchase”), subject to the completion of the offering. The price per share for the shares to be repurchased by the Company will be the same as the price per share payable by the underwriter to the Selling Stockholders. The underwriter will not receive any underwriting fees for the shares being repurchased by the Company. The Repurchase will be subject to completion of the offering and the satisfaction of other customary conditions. The offering is not conditioned upon the completion of the Repurchase.

J.P. Morgan is acting as the underwriter for the offering.

An automatic shelf registration statement (including a prospectus) relating to the offering of Common Stock was filed by LifeStance with the SEC on May 21, 2024 and became effective upon filing. Before you invest, you should read the prospectus in the shelf registration statement and the documents incorporated by reference therein and the prospectus supplement that the Company has filed with the SEC for more complete information about the Company and the offering. The offering will be made only by means of a prospectus and a related prospectus supplement relating to the offering, copies of which may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]. A copy of the prospectus and the related prospectus supplement relating to the offering may also be obtained free of charge by visiting EDGAR on the SEC’s website at www.sec.gov. 

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Nothing herein should be construed as an offer to sell, or the solicitation of an offer to buy, any shares of Common Stock subject to the Repurchase.

About LifeStance

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.

Forward-Looking Statements

This press release may contain “forward-looking” statements based on the Company’s beliefs and assumptions and on information currently available to the Company. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. For example, all statements we make regarding the terms of the proposed public offering and the Repurchase are forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by any forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our growth depends on our ability to recruit, acquire and retain clinicians; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; if we are unable to adapt to healthcare reform legislation and other changes in the healthcare industry and in healthcare spending, our business could be harmed; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the SEC.

For the reasons described above, we caution you against relying on any forward-looking statements, which should be read in conjunction with the other cautionary statements included elsewhere in this press release and risk factors discussed from time to time in the Company’s filings with the SEC, which can be found at the SEC’s website at http://www.sec.gov. Any forward-looking statement in this presentation speaks only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise any forward-looking statement after the date of this press release, whether as a result of new information, future developments or otherwise, except as may be required by law. No recipient should, therefore, rely on these forward-looking statements as representing the views of the Company or its management as of any date subsequent to the date of the press release.

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of 35,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”) at a public offering price of $8.15 per share, pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) from certain stockholders of the Company (the “Selling Stockholders”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.

In addition, the Company has agreed to purchase from the underwriter 6,000,000 shares of Common Stock to be sold by the Selling Stockholders in the offering, at a price per share equal to the price per share to be paid by the underwriter to the Selling Stockholders (the “Repurchase”). The Repurchase is conditioned upon the completion of the offering and the satisfaction of other customary conditions. The offering is not conditioned upon the completion of the Repurchase. The underwriter will not receive any compensation for the shares of Common Stock being purchased by the Company.

Subject to customary closing conditions, the offering and the Repurchase are expected to settle and close on or about May 12, 2026.

J.P. Morgan is acting as the underwriter for the offering.

An automatic shelf registration statement (including a prospectus) relating to the offering of Common Stock was filed by LifeStance with the SEC on May 21, 2024 and became effective upon filing. Before you invest, you should read the prospectus in the shelf registration statement and the documents incorporated by reference therein and the prospectus supplement that the Company has filed with the SEC for more complete information about the Company and the offering. The offering is being made only by means of a prospectus and a related prospectus supplement relating to the offering, copies of which may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]. A copy of the prospectus and the related prospectus supplement relating to the offering may also be obtained free of charge by visiting EDGAR on the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Nothing herein should be construed as an offer to sell, or the solicitation of an offer to buy, any shares of Common Stock subject to the
Repurchase.

About LifeStance

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.

Forward-Looking Statements

This press release may contain “forward-looking” statements based on the Company’s beliefs and assumptions and on information currently available to the Company. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. For example, all statements we make regarding the terms of the proposed public offering and the Repurchase are forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by any forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our growth depends on our ability to recruit, acquire and retain clinicians; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; if we are unable to adapt to healthcare reform legislation and other changes in the healthcare industry and in healthcare spending, our business could be harmed; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the SEC.

For the reasons described above, we caution you against relying on any forward-looking statements, which should be read in conjunction with the other cautionary statements included elsewhere in this press release and risk factors discussed from time to time in the Company’s filings with the SEC, which can be found at the SEC’s website at http://www.sec.gov. Any forward-looking statement in this presentation speaks only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise any forward-looking statement after the date of this press release, whether as a result of new information, future developments or otherwise, except as may be required by law. No recipient should, therefore, rely on these forward-looking statements as representing the views of the Company or its management as of any date subsequent to the date of the press release.

Shares of LifeStance Health Group (LFST - Free Report) have gained 21.8% over the past four weeks to close the last trading session at $7.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.39 indicates a potential upside of 31%.

The mean estimate comprises nine short-term price targets with a standard deviation of $1.58. While the lowest estimate of $8.00 indicates a 0.9% increase from the current price level, the most optimistic analyst expects the stock to surge 63.9% to reach $13.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.

However, an impressive consensus price target is not the only factor that indicates a potential upside in LFST. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.

Price, Consensus and EPS Surprise

Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Why LFST Could Witness a Solid UpsideThere has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The Zacks Consensus Estimate for the current year has increased 26.9% over the past month, as two estimates have gone higher compared to no negative revision.

Moreover, LFST currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Therefore, while the consensus price target may not be a reliable indicator of how much LFST could gain, the direction of price movement it implies does appear to be a good guide.

LifeStance Health Group (LFST - Free Report) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this outpatient mental health services provider, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For LifeStance Health Group, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsFor the current quarter, the company is expected to earn $0.02 per share, which is a change of +300.0% from the year-ago reported number.

Over the last 30 days, two estimates have moved higher for LifeStance Health compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 40%.

Current-Year Estimate RevisionsFor the full year, the earnings estimate of $0.11 per share represents a change of +450.0% from the year-ago number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for LifeStance Health. Over the past month, two estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 26.92%.

Favorable Zacks RankThe promising estimate revisions have helped LifeStance Health earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineInvestors have been betting on LifeStance Health because of its solid estimate revisions, as evident from the stock's 21.8% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.

A downtrend has been apparent in LifeStance Health Group (LFST - Free Report) lately. While the stock has lost 5.3% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.

The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this outpatient mental health services provider enhances its prospects of a trend reversal.

What is a Hammer Chart and How to Trade It?This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'

In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.

When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.

Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.

Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.

Here's What Makes the Trend Reversal More Likely for LFSTAn upward trend in earnings estimate revisions that LFST has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. That's because empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

Over the last 30 days, the consensus EPS estimate for the current year has increased 42.3%. What it means is that the sell-side analysts covering LFST are majorly in agreement that the company will report better earnings than they predicted earlier.

If this is not enough, you should note that LFST currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Moreover, a Zacks Rank of 1 for LifeStance Health is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve.

Seneca Foods (NASDAQ: SENEA - Get Free Report) and TreeHouse Foods (NYSE: THS - Get Free Report) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends. Analyst Ratings This is a breakdown

Posted by Defense World Staff on Apr 7th, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) insider Amy Simon sold 6,700 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total transaction of $164,686.00. Following the transaction, the insider directly owned 102,735 shares of the company’s stock, valued at $2,525,226.30. The trade was a 6.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beam Therapeutics Stock Down 1.7% Beam Therapeutics stock opened at $24.23 on Tuesday. The firm has a 50-day moving average price of $26.51 and a two-hundred day moving average price of $26.43. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of -23.99 and a beta of 2.18. Beam Therapeutics Inc. has a 52-week low of $13.52 and a 52-week high of $36.44.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported $2.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $3.46. The firm had revenue of $114.11 million during the quarter, compared to analyst estimates of $13.22 million. Beam Therapeutics had a negative net margin of 57.24% and a negative return on equity of 30.65%. Beam Therapeutics’s revenue was up 280.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.09) EPS. Research analysts expect that Beam Therapeutics Inc. will post -4.57 earnings per share for the current year.

Institutional Trading of Beam Therapeutics Several institutional investors have recently modified their holdings of the company. Purpose Unlimited Inc. acquired a new stake in shares of Beam Therapeutics in the fourth quarter valued at $80,000. Invesco Ltd. lifted its holdings in shares of Beam Therapeutics by 20.5% in the fourth quarter. Invesco Ltd. now owns 213,185 shares of the company’s stock valued at $5,909,000 after buying an additional 36,321 shares during the period. Axxcess Wealth Management LLC acquired a new stake in shares of Beam Therapeutics in the fourth quarter valued at $212,000. XTX Topco Ltd acquired a new stake in Beam Therapeutics during the fourth quarter valued at approximately $426,000. Finally, Virtus Investment Advisers LLC lifted its stake in Beam Therapeutics by 49.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 9,724 shares of the company’s stock valued at $270,000 after purchasing an additional 3,200 shares during the last quarter. Institutional investors and hedge funds own 99.68% of the company’s stock.

Analysts Set New Price Targets BEAM has been the subject of a number of analyst reports. Sanford C. Bernstein boosted their price target on Beam Therapeutics from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Citigroup boosted their price target on Beam Therapeutics from $64.00 to $68.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Wedbush boosted their price target on Beam Therapeutics from $57.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. UBS Group began coverage on shares of Beam Therapeutics in a report on Wednesday, January 7th. They issued a “neutral” rating and a $28.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Beam Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $49.36.

Read Our Latest Stock Report on BEAM

Beam Therapeutics Company Profile (Get Free Report)

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

Recommended Stories Five stocks we like better than Beam Therapeutics

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBeam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares

NEXT HEADLINE »Credo Technology Group (NASDAQ:CRDO) CTO Chi Fung Cheng Sells 2,434 Shares of Stock

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That’s according to Ben Lamm, CEO of Colossal Biosciences.

On episode 245 of the Moonshots with Peter Diamandis podcast, Lamm made the case that gene drive technology is the only scalable, humane answer.

“In New Zealand, in Australia, in parts of Africa, people are killing animals because they’re invasive species. They’re killing cats, they’re killing possums… that’s an animal welfare nightmare.”

Colossal’s proposed solution: genetically modified invasive animals that produce only male offspring, allowing populations to “live out their normal lives” before naturally dying out. No poison, no mass culling. Lamm also emphasized that Colossal’s proprietary gene drive technologies are “safer than what has ever been dispersed in the wild” and, critically, reversible: “we have the ability to roll it back.”

Texas has declared the screwworm a national emergency, with the pest currently spreading from Honduras through Mexico and threatening to “decimate our cattle and bison industry.” Diamandis noted the scale of the commercial opportunity: “dozens of species to be attacked and cost dozens of billions.”

Lamm’s broader point: 99% of synthetic biology and genome engineering talent focuses only on human healthcare, but the same technologies “apply to other use cases I think are even larger economically, but also have a bigger opportunity to help us.” He compared current invasive species control methods to “archaic ways of treating cancer versus what we know is here and what is coming.”

The Publicly Investable Gene-Editing Universe Colossal is private, so the question becomes where this thesis shows up in public markets. The three companies building the foundational CRISPR toolkit are CRISPR Therapeutics (NASDAQ:CRSP | CRSP Price Prediction), Beam Therapeutics (NASDAQ:BEAM), and Intellia Therapeutics (NASDAQ:NTLA).

CRISPR Therapeutics carries a $4.9 billion market cap with 17 analyst buy ratings and a consensus target of $83.35 against a current price of $51.22. Beam sits at $27.43 with 15 buy ratings and a $51.20 analyst target. Intellia, the smallest of the three at a $1.59 billion market cap, has surged 50% year-to-date to $13.49, with Phase 3 data on its lead HAE program expected mid-2026.

Their value here is as platform plays: the delivery systems, base editing precision, and in vivo editing capabilities they are refining for rare diseases are the same building blocks gene drive applications would require. If Lamm’s thesis proves out and gene drives move toward regulatory acceptance, these platforms become the infrastructure layer underneath it.

If gene drives become the standard, the companies that own the most precise, reversible genome editing platforms stand to benefit well beyond their current therapeutic pipelines. That’s the thread I’ll be watching.

As per recent news, Ondas completed its merger with U.S. defense prime contractor Mistral on April 24 in a $175 million deal, adding programs exceeding $1 billion and expanding direct prime participation across U.S. Department of War programs.

Cramer said he likes Halliburton Co (NYSE:HAL) very much as it has been a “good stock even in a bad oil market, so it's been a great stock in a good oil market.”

Lending support to his choice, Halliburton, on April 21, reported better-than-expected first-quarter financial results.

Nokia Oyj (NYSE:NOK) is a “winner,” Cramer said.

Cramer said he is a growth buyer, and Snap (NYSE:SNAP) does not have growth.

The Mad Money host said he likes Cameco Corporation (NYSE:CCJ) because it's a real uranium company.

When asked about Harley-Davidson Inc (NYSE:HOG), he said, “The technology is absolutely terrific, but the actual earnings, they're just blah. I can't go for it.”

Price Action:

Photo: katz / Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel in Sickle Cell Disease Published in April 1 Issue of the New England Journal of Medicine; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Investigational New Drug (IND) Application for BEAM-304 in PKU and Data from BEAM-301 in GSDIa Anticipated in 2026 Ended First Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) --   Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2026 financial results and provided updates across the company's hematology and genetic disease franchises.

Key Takeaways Beam Therapeutics posted Q1 revenues of $31.7M, topping estimates as collaboration revenues increased.BEAM plans a 2026 BLA filing for risto-cel after updated SCD study data showed progress.BEAM-302 showed durable AAT increases in AATD, with pivotal cohort enrollment set for 2H'26. Beam Therapeutics (BEAM - Free Report) incurred a loss of 91 cents per share in the first quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 87 cents. The company had reported a loss of $1.23 per share in the year-ago quarter.

Revenues totaled $31.7 million, beating the Zacks Consensus Estimate of $21 million. The company had recorded revenues of $7.4 million in the year-ago quarter. The top line primarily comprises license and collaboration revenues.

Year to date, shares of Beam Therapeutics have risen 13.5% against the industry’s 0.2% decline.

Image Source: Zacks Investment Research

BEAM's Q1 Results in DetailResearch and development expenses were $104.5 million in the first quarter, up 5.8% from the year-ago quarter.

General and administrative expenses surged 23.2% year over year to $34.4 million.

As of March 31, 2026, Beam Therapeutics had cash, cash equivalents and marketable securities worth $1.21 billion compared with $1.25 billion as of Dec. 31, 2025. The company expects its cash position, including the initial $100 million received and an anticipated additional $100 million from its financing agreement with Sixth Street, to support operations into mid-2029.

BEAM's Pipeline UpdatesBeam Therapeutics is developing its leading ex-vivo genome-editing candidate, risto-cel, in the phase I/II BEACON study for the treatment of patients with SCD, an inherited blood disorder.

The company presented updated data from the BEACON study in December 2025, which continued to show evidence of risto-cel’s differentiated treatment profile in SCD patients. BEAM plans to submit a biologics licensing application (BLA) for risto-cel by the end of 2026.

Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively.

BEAM-301 is being evaluated in a phase I/IIdose-exploration study in patients with GSDIa. Initial data from the study are expected in 2026.

The company is developing BEAM-302 in an ongoing phase I/II dose-escalation study for the treatment of AATD. In March, BEAM announced positive updated data from the study showing that BEAM-302 produced durable increases in functional AAT levels, significant reductions in mutant Z-AAT and generation of corrected M-AAT with a favorable safety profile across single doses up to 75 mg.

Following the FDA feedback, Beam Therapeutics aims to pursue an accelerated approval pathway for BEAM-302 and plans to initiate a global pivotal expansion cohort in the second half of 2026. The study is expected to enroll around 50 additional patients with AATD-related lung disease to support a future BLA filing.

Dosing in the ongoing phase I healthy volunteer study, evaluating BEAM-103, an anti-CD117 monoclonal antibody for the treatment of SCD, is expected to be completed in the first half of 2026.

The company expanded its liver-targeted genetic disease franchise with BEAM-304 for the treatment of phenylketonuria and plans to file an investigational new drug application with the FDA in 2026.

BEAM’s Zacks Rank & Stocks to ConsiderBeam Therapeutics currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the biotech sector are Amarin Corporation (AMRN - Free Report) , Indivior Pharmaceuticals (INDV - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.01 to $6.36. Over the same period, loss per share estimates for 2027 have also narrowed from $5.50 to $4.64. AMRN shares have risen 5.9% year to date.

Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 50.02%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.46. INDV shares have risen 10.4% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have declined from $2.14 to $1.75. Over the same period, EPS estimates for 2027 have decreased from $3.79 to $2.91. LQDA shares have gained 22.6% year to date.

Liquidia’s earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining occasions, with the average surprise being 39.38%.

May 13, 2026 07:00 ET  | Source: Beam Therapeutics

CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.

The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contact:

Holly Manning
Beam Therapeutics
[email protected]

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.

, /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Beam Therapeutics as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.

Beam Therapeutics AlphaDetect is dedicated to identifying everyone at risk for this progressive, irreversible genetic condition by elevating awareness and removing barriers to detection. The organization will provide free genetic testing for alpha-1 in their proprietary laboratory, at no cost to insurance or patients. In addition, they provide support from a committed engagement team for healthcare providers. These efforts will increase the availability of Alpha-1 detection tools and support at the practice level while also partnering with healthcare providers to strategically advance protocols and technologies across healthcare systems.

"Advancing Alpha-1 detection requires a focused effort," said Amy Simon, MD, Chief Medical Officer of Beam Therapeutics. "Working with the Alpha-1 Foundation, and now AlphaDetect as a subsidiary of A1F, there is an opportunity to accelerate detection across the Alpha-1 community aligned with clinical guidelines. These efforts will help bring much needed answers to patients and their families. As one of the inaugural sponsors of this effort, we're proud to have closely collaborated with AlphaDetect on this shared goal of increasing awareness and testing for Alpha-1."

"Alpha-1 is a progressive, genetic lung and liver condition where delays in detection may have real, irreversible consequences," said Julie Murray, CEO of AlphaDetect. "The ability to scale proven approaches to identifying at-risk patients, quickly and systematically, can inform timely decisions for those impacted. The support and commitment from Beam Therapeutics are important and appreciated as we continue to advance Alpha-1 detection."

Alpha-1 remains significantly underdiagnosed, with more than 90% of affected individuals estimated to be unidentified. It is also the leading known genetic risk factor for COPD and is associated with liver disease in both children and adults. Importantly, detection also provides a point of entry into the Alpha-1 community, opening the door to the comprehensive information, support, and resources needed for the journey ahead.

"This support builds on Beam Therapeutic's commitment to progressive clinical research to support the Alpha-1 community and represents an important step forward in how we approach detection," said Scott Santarella, CEO of the Alpha-1 Foundation. "By expanding these efforts through AlphaDetect, we can identify more individuals earlier and deliver on A1F's mission of improving their lives."

The latest clinical guidelines recommend testing for Alpha-1 in all individuals with COPD, treatment-resistant asthma, or unexplained liver disease. Yet real-world results fall far short of this. AlphaDetect is committed to closing the gap. Beam Therapeutics sponsorship and commitment will help AlphaDetect scale efforts to enhance provider education, broaden detection strategies, and work across the Alpha-1 community to identify individuals with Alpha-1.

About AlphaDetect 

AlphaDetect, founded in 2025, accelerates detection to uncover everyone genetically at risk for Alpha-1. Located in Durham, NC, AlphaDetect will operate as a limited liability company and a non-profit subsidiary of Alpha-1 Foundation, holding tax-exempt status under Section 501(c)3 of the Internal Revenue Code. 

For more information, visit https://alpha1.org/alphadetect/

Contact: Cindy Machles

917-453-9760

Email: [email protected]

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

For more information, visit beamtx.com

Contact: Holly Manning

Vice President, Investor Relations and External Communications

857-327-9449

[email protected]

About the Alpha-1 Foundation

The Alpha-1 Foundation, founded in 1995, is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by the condition worldwide. A1F has invested over $100 million to support Alpha-1 research and programs at 130 institutions in North America, Europe, the Middle East and Australia.

For more information, visit alpha1.org

Contact: Jeanne Kushner

Senior Director of Communications & Policy

877-228-7321

[email protected] 

SOURCE Alpha-1 Foundation

On May 15, 2026, ADAR1 Capital Management disclosed a new position in Beam Therapeutics (BEAM +2.79%), acquiring 1,446,375 shares in an estimated $40.13 million trade based on quarterly average pricing.

What happenedAccording to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, ADAR1 Capital Management, opened a new position in Beam Therapeutics, buying 1,446,375 shares. The estimated transaction value, based on the average closing price for the January–March 2026 quarter, was $40.13 million. At quarter end, the position was valued at $34.47 million, reflecting both the purchase and price changes.

What else to knowThis was a new position for the fund, making up 2.03% of 13F reportable assets as of March 31, 2026.Top five holdings after the filing:NASDAQ: ABVX: $155.22 million (9.4% of AUM)NASDAQ: PTGX: $104.78 million (6.4% of AUM)NASDAQ: ROIV: $91.02 million (5.5% of AUM)NASDAQ: IMVT: $66.55 million (4.0% of AUM)NYSEMKT: SPY: $49.39 million (3.0% of AUM)As of May 15, 2026, Beam Therapeutics shares were priced at $27.93, up 61.9% over the past year, outperforming the S&P 500 by 36.7 percentage points.Company overviewMetricValuePrice (as of market close May 15, 2026)$27.93Market Capitalization$2.87 billionRevenue (TTM)$164.01 millionNet Income (TTM)($65.04 million)Company snapshotDevelops precision genetic medicines targeting serious diseases, with lead candidates addressing sickle cell disease, beta thalassemia, T-cell acute lymphoblastic leukemia, and glycogen storage disorders.Operates a biotechnology business model focused on research, development, and commercialization of gene-editing therapies, generating revenue through product development, strategic collaborations, and licensing agreements.Serves patients with severe genetic and rare diseases, partnering with healthcare providers, research institutions, and pharmaceutical companies in the United States and globally.Beam Therapeutics is a biotechnology company specializing in precision genetic medicines, leveraging base editing technology to address a range of serious genetic disorders. The company advances a diversified pipeline through both proprietary research and strategic collaborations with leading academic and industry partners. With a focus on innovation and targeted therapies, Beam Therapeutics aims to establish a competitive position in the rapidly evolving field of gene editing.

Today's Change

(

2.79

%) $

0.82

Current Price

$

30.23

What this transaction means for investorsInvesting in pre-commercial gene therapy means betting on science that hasn't reached patients yet. You're wagering the technology works, clinical trials succeed, and the FDA approves before the cash runs out. ADAR1 Capital Management made that bet with a $40 million Beam Therapeutics position in Q1.

Beam develops gene-editing therapies for rare diseases but has no approved drugs yet. It has $1.2 billion in cash and burns around $140 million quarterly on R&D. Revenue comes entirely from collaboration milestone payments, not product sales.

The company expects to file for FDA approval of risto-cel (a sickle cell treatment) by late 2026 and will start pivotal trials for BEAM-302 (treating a rare genetic liver disease) in the second half of 2026. Both programs have shown promising early data and potential accelerated approval pathways.

For average investors, this is speculative biotech investing. The upside is significant if one or both drugs get approved and gain market traction. The risk is clinical trial failures, regulatory setbacks, or manufacturing issues derailing the pathway to profitability. Gene therapy is high-reward science with high execution risk.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics. The Motley Fool recommends Protagonist Therapeutics and Roivant Sciences. The Motley Fool has a disclosure policy.

3 Biotech Stocks That Could Benefit from the Patent CliffBeam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year.

Speaking at RBC Capital Markets’ Global Healthcare Conference in a discussion with Senior Biotechnology Research Analyst Luca Issi, Evans described Beam as a “next-generation gene-editing company” focused on base editing, a form of CRISPR designed to make permanent single-letter changes in genes without creating a double-strand break.

Get Beam Therapeutics alerts:

MarketBeat Week in Review – 3/4 – 3/8Evans said that distinction could allow Beam to make “more therapeutic edits” and “more precise edits,” including correcting mutations back to normal rather than only knocking genes out.

Alpha-1 Program Shows Dose Selection Progress A major focus of the discussion was BEAM-302, Beam’s program for alpha-1 antitrypsin deficiency. Evans said the program is designed to correct the single-letter misspelling in the alpha-1 gene back to normal, which he said is the first time anyone has been able to do so.

Beam Therapeutics Bolts Higher on Gene Therapy Licensing PaymentsEvans said earlier data showed that a 60-milligram dose achieved alpha-1 levels above 11 micromolar, a threshold he described as important because carriers who do not have the disease generally live above that line, while patients with progressive lung and liver damage are usually below it.

According to Evans, additional dose exploration around 60 milligrams, including a 75-milligram dose and a two-dose 60-milligram regimen, did not produce meaningful additional pharmacodynamic benefit. He said the results confirmed that 60 milligrams is the dose Beam wants to use.

Evans said the larger data set showed the 60-milligram dose produced an average alpha-1 level of 16 micromolar, with normal M protein levels above 90% and Z protein reduced by 84%.

“We had clearly and dramatically changed the disease physiology to at least a carrier physiology,” Evans said, adding that this supports Beam’s view that treated patients should not experience progressive disease going forward.

Safety and Redosing Discussed Issi asked about tolerability of a second 60-milligram dose, which Evans said was not as well tolerated as the first. Evans said it was difficult to know why, noting that preclinical data suggested eight weeks should have been enough time for the first lipid nanoparticle dose to clear. However, he said alpha-1 livers may differ in physiology and macrophage biology, potentially retaining some sensitivity.

Evans characterized the observed events as manageable. He said Beam saw higher infusion-related reactions, such as grade two events treated with Motrin, and one patient with a grade three AST/ALT elevation that was asymptomatic, did not require hospitalization, did not involve bilirubin changes and resolved quickly.

Evans said he did not believe the findings indicate that lipid nanoparticle redosing is not possible. He noted that Beam still plans to redose patients who previously received subtherapeutic 15-milligram and 30-milligram doses with the selected 60-milligram dose.

On liver enzyme elevations, Evans said the pattern Beam observed was consistent with a “classic LNP signal,” in which liver enzymes rise quickly and then fall quickly. He said the key safety considerations are rapid improvement within days and no bilirubin change, which he said Beam observed.

Bystander Editing and Protein Function Evans also addressed investor questions about bystander editing. He said BEAM-302 can create a mixture of corrected M protein and an M variant, a result Beam has known about and characterized over time.

Evans said Beam has shown that the variant is secreted normally, is functional and has a structure comparable to normal M protein. He also said the variant position is commonly varied in the human population and that the specific variant Beam creates is found in people and is not associated with disease.

He pointed to functional data showing direct inhibition of human neutrophil elastase using serum from treated patients, which he said demonstrated that the protein mixture created by the therapy is functional.

Regulatory Path and Liver Endpoints Evans said Beam has alignment with the FDA on an accelerated approval path for BEAM-302, describing it as a “classic accelerated approval” strategy rather than one reliant on newer regulatory mechanisms. He said the company is working with stable FDA review teams and that the agency’s main request was for 12 months of follow-up because alpha-1 levels can vary over time.

Evans said Beam plans to enroll 50 patients and follow them for one year before submitting the data. He said the biomarker package includes total alpha-1 levels, M protein levels, percentage of M protein, reduction in Z protein, protein functionality and inducibility.

On liver benefit, Evans said Beam believes BEAM-302 could help both lung and liver manifestations of alpha-1 antitrypsin deficiency by raising functional alpha-1 and lowering Z protein. He said Beam is conducting biopsies in Part B patients before treatment and at six and 12 months to assess whether aggregates resolve and whether fibrosis changes over time.

Evans said the Part B patients, who have more advanced liver disease, have so far tolerated the drug similarly to Part A patients, supporting an all-comer Cohort C.

Sickle Cell Program and Pricing Outlook Evans said Beam’s ex vivo sickle cell disease program, risto-cel, could have a BLA filing as early as the end of this year. He said Beam believes it has a strong manufacturing process, with a vein-to-vein time of just over four months, which he said could allow patients to be treated quickly and predictably.

Evans said risto-cel is aimed at severe sickle cell patients who may be candidates for a transplant-based option, while Beam also continues to work on in vivo approaches that could reach a broader sickle cell population over time.

On pricing, Evans said Beam would price a one-time alpha-1 therapy higher than one year of augmentation therapy, but said payers are sophisticated and evaluate long-term pharmacoeconomic value. He cited sickle cell disease as an example where high lifetime costs have supported genetic medicine pricing, while noting that it is too early to discuss specific pricing for alpha-1.

Evans said Beam believes alpha-1 antitrypsin deficiency has a strong value story because a one-time therapy could potentially address both lung and liver disease.

About Beam Therapeutics NASDAQ: BEAMBeam Therapeutics, Inc NASDAQ: BEAM is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Beam Therapeutics Right Now?Before you consider Beam Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.

While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Callodine Capital Management LP raised its position in shares of Plains GP Holdings, L.P. (NYSE: PAGP) by 125.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 540,000 shares of the pipeline company's stock after acquiring an additional 300,000 shares

HOUSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) (collectively, "Plains") today provided an update on the expected timing for completion of the Canadian NGL business divestiture to Keyera Corp. The transaction continues to advance through the regulatory process, including review by the Competition Bureau.

Posted by Defense World Staff on Apr 1st, 2026

Exchange Traded Concepts LLC decreased its holdings in Plains GP Holdings, L.P. (NYSE:PAGP – Free Report) by 14.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,689 shares of the pipeline company’s stock after selling 29,234 shares during the period. Exchange Traded Concepts LLC owned about 0.09% of Plains GP worth $3,248,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of PAGP. Whittier Trust Co. of Nevada Inc. boosted its holdings in Plains GP by 56.8% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 1,781 shares of the pipeline company’s stock valued at $32,000 after purchasing an additional 645 shares during the period. Larson Financial Group LLC purchased a new stake in Plains GP during the 3rd quarter worth about $46,000. Lazard Asset Management LLC increased its holdings in Plains GP by 36.5% during the 2nd quarter. Lazard Asset Management LLC now owns 3,030 shares of the pipeline company’s stock worth $58,000 after purchasing an additional 811 shares during the period. Asset Dedication LLC acquired a new stake in Plains GP in the 2nd quarter valued at about $83,000. Finally, CWM LLC raised its position in Plains GP by 159.3% in the 3rd quarter. CWM LLC now owns 7,477 shares of the pipeline company’s stock valued at $136,000 after purchasing an additional 4,594 shares in the last quarter. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Plains GP Price Performance Shares of NYSE PAGP opened at $24.28 on Wednesday. The stock’s 50-day simple moving average is $22.30 and its 200-day simple moving average is $19.76. The firm has a market capitalization of $4.81 billion, a PE ratio of 45.81 and a beta of 0.56. Plains GP Holdings, L.P. has a fifty-two week low of $16.60 and a fifty-two week high of $24.75. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.92 and a current ratio of 1.01.

Plains GP Dividend Announcement The business also recently announced a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Friday, January 30th were issued a $0.4175 dividend. The ex-dividend date was Friday, January 30th. This represents a $1.67 annualized dividend and a dividend yield of 6.9%. Plains GP’s dividend payout ratio is presently 129.46%.

Analyst Ratings Changes A number of equities analysts have recently commented on the company. Barclays boosted their price objective on Plains GP from $17.00 to $18.00 and gave the stock an “underweight” rating in a research report on Monday, February 9th. Stifel Nicolaus raised their target price on shares of Plains GP from $23.00 to $25.00 and gave the company a “buy” rating in a report on Friday, March 6th. Mizuho set a $23.00 price target on shares of Plains GP in a research note on Friday, January 23rd. Wells Fargo & Company boosted their price target on shares of Plains GP from $21.00 to $22.00 and gave the stock an “equal weight” rating in a report on Friday, March 13th. Finally, Bank of America downgraded shares of Plains GP from a “neutral” rating to an “underperform” rating and set a $19.00 price objective on the stock. in a research report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, five have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Plains GP presently has an average rating of “Hold” and an average price target of $21.60.

View Our Latest Research Report on PAGP

About Plains GP (Free Report)

Plains GP Holdings, L.P. (NYSE: PAGP) serves as the general partner of Plains All American Pipeline, L.P., one of North America’s leading energy infrastructure companies. Through its ownership of a 2% general partner interest and incentive distribution rights (IDRs), Plains GP Holdings participates in the governance and cash distribution structure of a diversified portfolio of crude oil and natural gas liquids gathering, transportation, storage, and terminaling assets.

The company’s primary business activities include overseeing the strategic direction and capital allocation decisions for its affiliated midstream operations.

Featured Stories Five stocks we like better than Plains GP Want to see what other hedge funds are holding PAGP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Plains GP Holdings, L.P. (NYSE:PAGP – Free Report).

Receive News & Ratings for Plains GP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plains GP and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEExchange Traded Concepts LLC Has $3.36 Million Stock Position in Agree Realty Corporation $ADC

NEXT HEADLINE »Exchange Traded Concepts LLC Increases Stock Position in Invesco Senior Loan ETF $BKLN

Posted by Defense World Staff on Apr 13th, 2026

Massachusetts Financial Services Co. MA cut its stake in Plains GP Holdings, L.P. (NYSE:PAGP – Free Report) by 4.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,537,077 shares of the pipeline company’s stock after selling 401,450 shares during the period. Massachusetts Financial Services Co. MA owned 4.82% of Plains GP worth $182,540,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Stratos Wealth Partners LTD. purchased a new stake in Plains GP in the fourth quarter worth about $269,000. HF Advisory Group LLC lifted its holdings in Plains GP by 37.9% in the fourth quarter. HF Advisory Group LLC now owns 266,276 shares of the pipeline company’s stock worth $5,097,000 after buying an additional 73,248 shares during the period. Ellsworth Advisors LLC lifted its holdings in Plains GP by 19.3% in the fourth quarter. Ellsworth Advisors LLC now owns 67,595 shares of the pipeline company’s stock worth $1,363,000 after buying an additional 10,948 shares during the period. Adams Asset Advisors LLC lifted its holdings in Plains GP by 19.5% in the fourth quarter. Adams Asset Advisors LLC now owns 57,753 shares of the pipeline company’s stock worth $1,105,000 after buying an additional 9,442 shares during the period. Finally, Alliance Wealth Advisors LLC lifted its holdings in Plains GP by 21.6% in the fourth quarter. Alliance Wealth Advisors LLC now owns 16,651 shares of the pipeline company’s stock worth $319,000 after buying an additional 2,960 shares during the period. 88.30% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes A number of equities analysts have weighed in on PAGP shares. Wells Fargo & Company raised their target price on shares of Plains GP from $21.00 to $22.00 and gave the company an “equal weight” rating in a research note on Friday, March 13th. Zacks Research downgraded shares of Plains GP from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Truist Financial started coverage on shares of Plains GP in a research note on Tuesday, March 24th. They set a “buy” rating and a $23.00 target price for the company. Bank of America downgraded shares of Plains GP from a “neutral” rating to an “underperform” rating and set a $19.00 target price for the company. in a research note on Wednesday, January 28th. Finally, Mizuho set a $23.00 target price on shares of Plains GP in a research note on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, five have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Plains GP currently has a consensus rating of “Hold” and a consensus target price of $21.90.

Check Out Our Latest Report on PAGP

Plains GP Price Performance Shares of NYSE PAGP opened at $23.58 on Monday. The company has a market capitalization of $4.67 billion, a price-to-earnings ratio of 44.49 and a beta of 0.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.92 and a current ratio of 1.01. The company has a 50 day simple moving average of $22.82 and a two-hundred day simple moving average of $20.06. Plains GP Holdings, L.P. has a fifty-two week low of $16.68 and a fifty-two week high of $24.75.

Plains GP Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Friday, May 1st will be given a dividend of $0.4175 per share. The ex-dividend date of this dividend is Friday, May 1st. This represents a $1.67 annualized dividend and a dividend yield of 7.1%. Plains GP’s dividend payout ratio (DPR) is 129.46%.

Plains GP Profile (Free Report)

Plains GP Holdings, L.P. (NYSE: PAGP) serves as the general partner of Plains All American Pipeline, L.P., one of North America’s leading energy infrastructure companies. Through its ownership of a 2% general partner interest and incentive distribution rights (IDRs), Plains GP Holdings participates in the governance and cash distribution structure of a diversified portfolio of crude oil and natural gas liquids gathering, transportation, storage, and terminaling assets.

The company’s primary business activities include overseeing the strategic direction and capital allocation decisions for its affiliated midstream operations.

Featured Articles Five stocks we like better than Plains GP

Receive News & Ratings for Plains GP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plains GP and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMassachusetts Financial Services Co. MA Decreases Position in Manulife Financial Corp $MFC

NEXT HEADLINE »Massachusetts Financial Services Co. MA Purchases 1,300,982 Shares of XP Inc. $XP

Most retirees are forced to choose between yield and safety — discover two rare investments that deliver 8%+ income without forcing that painful tradeoff. One is a bond ETF that actually grows its dividend (something almost no bond fund can claim), and the other is a cash-flow machine with 12.5% guided distribution growth. In a volatile market where most high yields are getting crushed, these two holdings have the balance sheet strength, inflation protection, and structural advantages to keep paying and growing.

Posted by Defense World Staff on Apr 22nd, 2026

Eagle Global Advisors LLC reduced its stake in shares of Plains GP Holdings, L.P. (NYSE:PAGP – Free Report) by 3.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,124,930 shares of the pipeline company’s stock after selling 43,570 shares during the period. Eagle Global Advisors LLC owned 0.57% of Plains GP worth $21,531,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Caprock Group LLC purchased a new stake in shares of Plains GP during the 3rd quarter valued at approximately $3,088,000. CWA Asset Management Group LLC raised its position in shares of Plains GP by 19.3% during the 4th quarter. CWA Asset Management Group LLC now owns 156,306 shares of the pipeline company’s stock valued at $2,992,000 after buying an additional 25,321 shares during the period. Osaic Holdings Inc. raised its position in shares of Plains GP by 75.3% during the 2nd quarter. Osaic Holdings Inc. now owns 291,320 shares of the pipeline company’s stock valued at $5,661,000 after buying an additional 125,169 shares during the period. Turtle Creek Wealth Advisors LLC raised its position in shares of Plains GP by 16.8% during the 3rd quarter. Turtle Creek Wealth Advisors LLC now owns 800,863 shares of the pipeline company’s stock valued at $14,608,000 after buying an additional 115,020 shares during the period. Finally, CUSHING ASSET MANAGEMENT LP dba NXG INVESTMENT MANAGEMENT raised its position in shares of Plains GP by 1.2% during the 3rd quarter. CUSHING ASSET MANAGEMENT LP dba NXG INVESTMENT MANAGEMENT now owns 3,585,000 shares of the pipeline company’s stock valued at $65,390,000 after buying an additional 42,000 shares during the period. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Wall Street Analyst Weigh In Several analysts have recently commented on PAGP shares. Mizuho set a $23.00 price target on shares of Plains GP in a research report on Friday, January 23rd. Bank of America lowered shares of Plains GP from a “neutral” rating to an “underperform” rating and set a $19.00 price target on the stock. in a research report on Wednesday, January 28th. Truist Financial started coverage on shares of Plains GP in a research report on Tuesday, March 24th. They set a “buy” rating and a $23.00 price target on the stock. Stifel Nicolaus lifted their price target on shares of Plains GP from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Finally, Citigroup lifted their price target on shares of Plains GP from $17.00 to $20.00 and gave the company a “neutral” rating in a research report on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Plains GP has a consensus rating of “Hold” and an average price target of $21.90.

Read Our Latest Report on Plains GP

Plains GP Stock Up 0.7% Shares of NYSE PAGP opened at $22.84 on Wednesday. The firm has a market cap of $4.52 billion, a price-to-earnings ratio of 43.10 and a beta of 0.50. The company has a quick ratio of 0.92, a current ratio of 1.01 and a debt-to-equity ratio of 0.49. Plains GP Holdings, L.P. has a 52-week low of $16.68 and a 52-week high of $24.75. The business’s 50 day moving average is $23.14 and its two-hundred day moving average is $20.29.

Plains GP Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Friday, May 1st will be given a $0.4175 dividend. The ex-dividend date of this dividend is Friday, May 1st. This represents a $1.67 dividend on an annualized basis and a yield of 7.3%. Plains GP’s payout ratio is presently 129.46%.

Plains GP Company Profile (Free Report)

Plains GP Holdings, L.P. (NYSE: PAGP) serves as the general partner of Plains All American Pipeline, L.P., one of North America’s leading energy infrastructure companies. Through its ownership of a 2% general partner interest and incentive distribution rights (IDRs), Plains GP Holdings participates in the governance and cash distribution structure of a diversified portfolio of crude oil and natural gas liquids gathering, transportation, storage, and terminaling assets.

The company’s primary business activities include overseeing the strategic direction and capital allocation decisions for its affiliated midstream operations.

Recommended Stories Five stocks we like better than Plains GP Want to see what other hedge funds are holding PAGP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Plains GP Holdings, L.P. (NYSE:PAGP – Free Report).

Receive News & Ratings for Plains GP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plains GP and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEEagle Global Advisors LLC Sells 68,233 Shares of Williams Companies, Inc. (The) $WMB

NEXT HEADLINE »Mplx Lp $MPLX Stock Position Lessened by Eagle Global Advisors LLC

On May 15, 2026, Energy Income Partners disclosed a first-quarter buy of 120,765 shares of Plains GP Holdings (PAGP +0.82%), an estimated $2.64 million trade based on quarterly average pricing.

What happenedAccording to the SEC filing dated May 15, 2026, Energy Income Partners increased its stake in Plains GP Holdings by 120,765 shares during the first quarter. The estimated transaction value was $2.64 million based on average closing prices for the quarter. The quarter-end value of the position increased by $48.44 million, a figure that reflects both additional shares purchased and share price appreciation during the quarter.

What else to knowThis was a buy; the position now represents 3.51% of Energy Income Partners, LLC’s 13F reportable assets under management.Top holdings after the filing:NYSE:EPD: $519.59 million (8.4% of AUM)NYSE:ET: $486.50 million (7.8% of AUM)NYSE:MPLX: $294.34 million (4.7% of AUM)NYSE:KMI: $249.30 million (4.0% of AUM)NYSE:NFG: $243.34 million (3.9% of AUM)As of Friday, shares of Plains GP Holdings were priced at $24.35, up 38% over the past year and outperforming the S&P 500’s roughly 28% gain in the same period.Company OverviewMetricValueRevenue (TTM)$45.26 billionNet Income (TTM)$196.00 millionDividend Yield6.5%Price (as of Friday)$24.35Company SnapshotPlains GP Holdings operates crude oil and natural gas liquids (NGL) pipelines, gathering systems, storage, and processing facilities across the United States and Canada.The firm generates revenue primarily through fee-based transportation, storage, and logistics services for crude oil and NGLs, with additional income from terminalling, fractionation, and processing.It serves oil and gas producers, refiners, and other midstream and downstream energy customers seeking reliable infrastructure and logistics solutions.Plains GP Holdings is a leading midstream energy company specializing in the transportation, storage, and processing of crude oil and natural gas liquids across North America. The company leverages an extensive asset base, including thousands of miles of pipelines and significant storage capacity, to provide critical infrastructure services to the energy sector. Its fee-based business model and diverse customer base position it as a key logistics partner within the oil and gas value chain.

What this transaction means for investorsThis purchase comes at an interesting time for Plains, which entered this year with the momentum to raise its full-year adjusted EBITDA guidance by $130 million to a midpoint of $2.88 billion, citing stronger oil market conditions and continued contributions from assets it plans to divest. In the firm’s latest earnings report, CEO Willie Chiang said global events have reinforced the importance of reliable energy infrastructure and argued the company is well-positioned as a key link between U.S. production and global demand.

The operating numbers support that optimism. First-quarter crude oil adjusted EBITDA increased 4% year over year to $582 million, helped by higher pipeline volumes and recent acquisitions. Total crude oil pipeline volumes climbed 10% to more than 10 million barrels per day. Plains also continues to generate cash while paying a distribution that currently yields about 7.5%. Management expects roughly $1.85 billion in adjusted free cash flow this year.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kinder Morgan. The Motley Fool recommends Enterprise Products Partners. The Motley Fool has a disclosure policy.

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of FS KKR Capital Corp. (NYSE: FSK) between May 8, 2024 and February 25, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased FS KKR Capital securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the FS KKR Capital class action, go to https://rosenlegal.com/submit-form/?case_id=64089 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) FS KKR Capital overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) FS KKR Capital overstated the valuation of its portfolio investments and/or overstated the effectiveness of FS KKR Capital’s portfolio valuation process; (3) FS KKR Capital overstated the durability of its quarterly distribution strategy; and (4) as a result of the foregoing, defendants’ positive statements about FS KKR Capital’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the FS KKR Capital class action, go to https://rosenlegal.com/submit-form/?case_id=64089 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Alert: Claims Focus on Alleged Misrepresentations About Non-Accrual Portfolio Management That Cost FSK Investors $880 Million in Fair Value Losses Across Two Corrective Disclosures

, /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of FS KKR Capital Corp. (NYSE: FSK) securities of a pending securities class action.

THE CASE: A class action seeks to recover damages for investors who purchased FSK securities between May 8, 2024 and February 25, 2026.

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you can recover losses or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

FSK shares fell $2.03 per share, or 15.24%, closing at $11.29 on February 26, 2026, after the Company revealed its non-accrual rate had climbed above the long-term BDC industry average. Investors have until July 6, 2026 to seek lead plaintiff status.

The Alleged Non-Accrual Acceleration From 1.7% to 3.4% at Fair Value

A business development company cannot sustain its distribution strategy or maintain its debt-to-equity compliance when a growing share of its loan portfolio stops generating income. For FS KKR Capital, the complaint chronicles a dramatic reversal in the credit health of its investment book.

As alleged in the filing, the Company told investors quarter after quarter that its workout team was making "significant progress restructuring certain non-accruing investments." Non-accruals at fair value had reportedly declined from 5.5% in December 2023 to just 1.7% by September 2024. The lawsuit contends this progress narrative masked deepening problems in legacy holdings that management knew or should have known were deteriorating.

By June 2025, non-accruals at fair value had nearly doubled to 3.0%. By December 2025, they reached 3.4% at fair value and 5.5% at amortized cost, a level the Company's own Chief Investment Officer was forced to acknowledge exceeded the long-term BDC industry average of approximately 3.8% at cost.

Legacy Portfolio Management and the Workout Team's Alleged Failures

The action claims FS KKR's reported success in restructuring troubled credits was overstated. Specifically, the complaint identifies multiple portfolio companies — including Production Resource Group, 48forty, Kellermeyer Bergensons Services, Worldwise, Medallia, and Cubic Corp — whose deterioration drove hundreds of millions in realized and unrealized losses:

Production Resource Group, 48forty, Kellermeyer Bergensons Services, and Worldwise were identified during the August 2025 earnings disclosure, when fair value fell $474 million in a single quarter Medallia and Cubic Corp emerged as additional problem credits in the February 2026 disclosure, which revealed another $406 million fair value decline The Company acknowledged that these identified companies represented only 50% of total net realized and unrealized losses, suggesting broader portfolio weakness Non-accrual rates at amortized cost surged from 3.5% in Q1 2025 to 5.5% by year-end, a 57% increase in three quarters Calculate your potential recovery or call (212) 363-7500.

Alleged Non-Accrual Impact by the Numbers

The financial consequences of the alleged credit deterioration were severe. Net asset value per share eroded from $24.32 as of March 31, 2024 (the quarter in which the Class Period began) to $20.89 by December 2025, a cumulative decline of $3.43 per share, or 14.1%. Full year 2024 adjusted net realized and unrealized losses widened to negative $0.72 per share compared to negative $0.56 the prior year. The total fair value of investments contracted from approximately $14.2 billion to $13.0 billion.

The complaint asserts these losses were foreseeable because the underlying credit deterioration was occurring while management publicly assured investors the workout process was succeeding.

"The complaint raises serious questions about whether investors received accurate information regarding the trajectory of FS KKR's non-accrual portfolio and the effectiveness of its restructuring efforts." -- Joseph E. Levi, Esq.

Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

Frequently Asked Questions About the FSK Lawsuit

Q: Who is eligible to join the FSK investor lawsuit? A: Investors who purchased FSK stock or securities between May 8, 2024 and February 25, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: How much did FSK stock drop? A: Shares fell approximately 15.24%, a decline of $2.03 per share, after the Company disclosed deepening non-accrual problems and slashed its dividend on February 25, 2026. An earlier corrective disclosure on August 6, 2025 caused an additional 8.20% decline.

Q: What specific misstatements does the FSK lawsuit allege? A: The complaint alleges FS KKR Capital made materially false or misleading statements regarding the effectiveness of its portfolio restructuring efforts, the accuracy of its investment valuations, and the sustainability of its quarterly distributions. When the true state was revealed, the stock price declined sharply.

Q: What do FSK investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my FSK shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE Levi & Korsinsky, LLP